Back to Directory

Brigid Bio

Founded 2025
Developing monoclonal antibody therapies for invasive fungal infections

Brigid Bio is a biopharmaceutical company developing human monoclonal antibodies for invasive fungal infections, including infections caused by drug-resistant pathogens. Its discovery platform combines proteomics and transcriptomics to identify fungal cell wall proteins for antibody targeting.

The company’s preclinical programmes focus on Candida and Aspergillus infections, with research exploring antibody treatment alongside existing antifungal medicines for patients at high risk of serious disease.